Submillisievert Computed Tomography of the Chest in Contact Investigation for Drug-Resistant Tuberculosis

Seung Chul Lee,¹ * Soon Ho Yoon,²,³* Jin Mo Goo,²,³ Jae-Young Yim,⁴ and Chang-Ki Kim⁵

¹Division of HIV and Tuberculosis Control, Korea Centers for Disease Control and Prevention, Seoul, Korea; ²Department of Radiology, Seoul National University College of Medicine, Seoul, Korea; ³Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Korea; ⁴Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea; ⁵Korean Institute of Tuberculosis, Seoul, Korea

*Seung Chul Lee and Soon Ho Yoon contributed equally to this work.

INTRODUCTION

Tuberculosis (TB) remains a major global health concern, with an estimated 9.6 million new cases and 1.2 million deaths in 2014 (1). Emerging drug resistance makes the control of TB especially difficult. Currently, one-quarter of estimated multi-drug resistant tuberculosis (MDR-TB) patients are detected, and only a half of them are successfully treated whereas 63% of drug-sensitive TB are detected and 85% of them are successfully treated (1). In Korea, approximately 1,000 patients with newly diagnosed MDR-TB have been reported annually (2).

The transmission of the drug-resistant TB strain is primarily responsible for MDR-TB cases (3). Close contacts with MDR-TB patients are persons at high risk for latent TB infection (LTBI) and active MDR-TB. Contact investigation in households of MDR-TB patients showed 47.2% of LTBI and 7.8% of secondary active TB (4). Secondary active TB appeared within 1 year of diagnosis of index MDR-TB in over half of patients, and had multi-drug resistance concordant with index MDR-TB in up to 90% (5).

LTBI treatment is important for contact with drug-sensitive TB in preventing the development of secondary active TB. Nevertheless, there is no established effective treatment for contact with LTBI to MDR-TB (6), with frequent side effects and at least a 6-month period of treatment, which cause treatment discontinuation in 58%–100% of contacts (7). Management of contacts with MDR-TB largely depends on close observation (8). Thus, early identification of secondary active MDR-TB in contacts is crucial (3,5). However, close observation with chest radiographic and symptom screening may be ineffective in detecting secondary MDR-TB at an early stage, due to lack of symptoms, scarcity of sputum (9), and vagueness of chest radiograph (10). Immunologic studies including tuberculin skin test and interferon gamma release assay (IGRA) had limitations in predicting the development of active TB from LTBI (11). Contacts are known to have low adherence to LTBI management, and are at risk of being lost to follow-up (12).

Several new biomarkers have been suggested for predicting progression from LTBI to active TB, but are not yet applicable and take time for clinical implementation (11). Computed tomography (CT) is one of the most widely used imaging modalities, offering high-resolution anatomic evaluation, though radiation is of concern (13). We preliminarily introduced submil-
MATERIALS AND METHODS

Contact investigation
The index patient was a 35-year-old man with a 3-month history of a productive cough and a poorly controlled diabetes. The acid-fast bacilli (AFB) smear of his sputum was positive with a 3+ grade. The Xpert/RIF assay was positive for Mycobacterium tuberculosis and rifampicin resistance, followed by culture positivity. The drug susceptibility test confirmed resistances to isoniazid (Carolina Medical Products Co., Farmville, NC, USA), rifampin (sanofi-aventis U.S. LLC, Bridgewater, NJ, USA), and rifabutin (Pfizer Inc., New York, NY, USA).

Investigation of the present study was initiated for eligible close contacts as follows: individuals older than 20 years old, with household contact or working in the same room for more than 8 hours per day (ClinicalTrials.gov Identifier: NCT02454738). Close contacts underwent baseline, 3-month, 1-year follow-up submillisievert chest CT scans, along with conventional contact investigation. For full technical details of contact investigation, bacteriology and genotyping, see the Supplementary 1.

Submillisievert chest CT scanning
Unenhanced chest CT scans were obtained using a 64-channel multidetector CT scanner (Discovery CT750 HD; GE Healthcare, Waukesha, WI, USA) at a peak kilo-voltage of 120 kV and a tube current of 5 mAs. Patients were scanned craniocaudally from the lung apex to the costophrenic angle in the supine position at full inspiration during a single breath-hold. CT parameters were collimation of 0.625 mm × 64, a pitch of 0.984, and a gantry rotation time of 0.5 seconds, with images reconstructed by model-based iterative reconstruction (Veo; GE Healthcare), and 1.25-mm slice thickness in the transverse plane and 2.5-mm slice thickness in the coronal plane. Effective doses of chest CT scans were estimated by multiplying dose-length product by a chest-conversion factor of 0.0145 (14).

RESULTS

Baseline contact investigation and CT scanning
Seven close contacts who worked with the index patient were identified. There was no family living together. One contact was reluctant to contact investigation and study enrollment, so contact investigation was performed in six contacts (contact 1 to 6) (mean age, 35 years; age range, 30–37; male:female, 5:1) (Table 1). All six contacts denied any symptoms or signs, and had normal chest radiographic findings on baseline examination. Half of six contacts (contact 1, 3, and 6) turned out to have LTBI.

Baseline CT scans identified incidental parenchymal abnormalities in two of six contacts. In contact 1, a few ill-defined nodules and branching opacities were localized in the superior segment of the right lower lobe (Fig. 1). In contact 2, two sub-centimeter nodules were found in the apical segment of the right upper lobe (Fig. 2).

Follow-up contact investigation and CT scanning
Due to concern about branching opacities and nodules for baseline CT scan in contact 1, follow-up was advanced by one month. Contact 1 denied any symptoms or signs at a 2-month follow-up. Sputum AFB smear, Xpert/RIF test, and mycobacterial culture were negative. CT scan depicted increase of pre-existing nodular and branching opacities in the same lobe, while chest radiograph showed subtle opacities in the right upper lung zone (Fig. 1). The pulmonologist decided to perform a bronchoalveolar lavage. Pre-procedural chest radiograph for bronchoscopy was taken 3 weeks later, showing overt progression of radiologic abnormalities. The bronchoalveolar lavage fluid was positive for M. tuberculosis and rifampin resistance on same-day Xpert/RIF test, leading to immediate isolation. The mycobacterial cul-

Table 1. Summary of contact investigation in close contacts to MDR-TB

| ID | Sex | Age, yr | Symptoms and signs | Chest radiograph | Tuberculin skin test, mm | TB response on IGRA, IU/mL | LTBI* |
|----|-----|---------|---------------------|------------------|--------------------------|--------------------------|-------|
| 1  | Male| 29      | Negative            | Normal           | 17                       | 0.60                     | Yes   |
| 2  | Male| 34      | Negative            | Normal           | 0                        | Not done†                | No    |
| 3  | Male| 33      | Negative            | Normal           | 13                       | −0.24                    | No    |
| 4  | Male| 36      | Negative            | Normal           | 13                       | 3.14                     | Yes   |
| 5  | Female| 32      | Negative            | Normal           | 10                       | 0.05                     | No    |
| 6  | Male| 33      | Negative            | Normal           | Not assessable§           | 6.87                     | Yes   |

The Korean national guideline for contact investigation for TB adopts a two-step strategy for LTBI, sequentially performing tuberculin skin test and IGRA. MDR-TB = multi-drug resistant tuberculosis, TB = tuberculosis, IGRA = interferon gamma release assay, LTBI = latent tuberculosis infection.

*LTBI was assessed to be present when both tuberculin skin test and IGRA were positive. Cut-offs for positivity of tuberculin skin test and IGRA (corrected for Nil response) were 10 mm and 0.35 IU/mL, respectively. †Contact 2 did not have a positive conversion in the secondary tuberculin skin test which was performed 3 months later. ‡Contact 6 had a history of positive tuberculin skin test before, so tuberculin test was omitted.

Ethics statement
The study protocol was approved by our Institutional Review Board of Seoul National University Hospital (IRB No. 1501-113-644). Written informed consents were obtained by all participants.
ture of bronchoalveolar lavage fluid was positive after 13 days in liquid media and 8 weeks in solid media. The result of the drug susceptibility test in contact 1 was identical with that of the index case. The pattern of spoligotyping and 24-loci MIRU-VNTR analysis are identical between index and secondary MDR-TB. Contact 1 was matched identically (*M. tuberculosis* strain, Beijing; 24-loci MIRU-VNTR, 244233524425173353824). Contact 1 was
treated with kanamycin, pyrazinamide, moxifloxacin, prothionamide, and cycloserine. During the treatment, serial expectorated sputa were negative for smear and culture. He was cured after 1.5-year of treatment.

Other contacts did not have symptoms at 3-month and 1-year follow-up. In contact 2, a 3-month follow-up CT scan showed a slight increase in nodule size. One of two nodules decreased on follow-up CT scan 1 year later (Fig. 2). There were no abnormalities in follow-up CT scans in four of six contacts, and none with negative initial LTBI test had a positive conversion in the secondary LTBI test.

**Radiation dose of submillisievert chest CT scanning**
Median dose-length product and effective dose per CT scan were 14.91 milligray-cm (range, 13.08–16.90) and 0.21 millisievert (range, 0.19–0.25), respectively, with 1-year cumulative dose-length product of 44.52 milligray-cm (range, 43.28–49.18) and 1-year cumulative effective dose of 0.65 millisievert (range, 0.63–0.71).

**DISCUSSION**

Radiation exposure ought to be the main concern for the use of chest CT scans in contact investigation of TB (13). Low dose ionizing radiation of medical imaging below 100 millisievert may increase cancer risk in children, who are more radiosensitive than adults (15). However, the estimated effective dose of our submillisievert chest CT scans (average, 0.21 millisievert; range, 0.19–0.25) is much lower than that of conventional chest CT scans (average, 7.0 millisievert; range, 4.0–18.0), two times higher than posteroanterior and lateral chest examinations (average, 0.10 millisievert; range, 0.05–0.24), and ten times higher than posteroanterior chest radiographs (average, 0.02 millisievert; range, 0.01–0.05) (16). Submillisievert radiation is negligible for cancer risk when compared with radiation from natural source of 3.1 millisievert per year in adults.

TB granuloma is the earliest pulmonary parenchymal abnormality (17). Baseline CT scan depicted sub-centimeter-sized nodules suspected of TB granuloma in contact 1 and 2, which were not shown on chest radiograph. However, the presence of parenchymal CT abnormalities in contacts are not indicative of active disease without overt CT findings of active TB, such as extensive tree-in-bud appearance and cavities (18). The hallmark of active TB is the progression of parenchymal abnormalities on follow-up. Thus, we introduced repeated submillisievert CT scans for determining active disease. Indeed, repeated CT examinations revealed that TB granuloma gradually progressed in contact 1, while sub-centimeter-sized nodules was stabilized in contact 2, potentially in line with the inter-individual and within-host variability of TB (17).

Based on the radiologic progression of repeated submillisievert CT scans, contact 1 was further evaluated and diagnosed with secondary MDR-TB in asymptomatic periods. This led to a favorable treatment outcome with minimal residue, and early isolation of MDR-TB at the lowest infectivity, consequently minimizing transmission of drug-resistant strain. In a risk-benefit perspective, submillisievert chest CT may be considered in adult contacts at risk for MDR-TB in high-resource setting, such as health care workers (19). Given that active TB most commonly develops in the first 2 years of TB exposure, annual follow-up
chest CT may be performed up to the first 2 years. In addition, submillisievert chest CT may not be recommended in contacts with negative LTBI but it needs to be considered that false-negative rate of LTBI test is 8%–19% and increased in immunocompromised contacts (20). Further investigation is required for these issues.

In conclusion, early identification of secondary MDR-TB is feasible with submillisievert chest CT scans in contact investigations of MDR-TB, minimizing of MDR-TB transmission and offering a favorable treatment outcome.

DISCLOSURE

The authors have no potential conflicts of interest to disclose.

AUTHOR CONTRIBUTION

Conceptualization: Lee SC, Yoon SH, Goo JM, Yim JJ. Data curation: Lee SC, Yoon SH, Goo JM, Yim JJ, Kim CK. Formal analysis: Lee SC, Yoon SH, Goo JM, Yim JJ, Kim CK. Investigation: Lee SC, Yoon SH, Goo JM, Yim JJ, Kim CK. Writing - original draft: Yoon SH. Writing - review & editing: Lee SC, Yoon SH, Goo JM, Yim JJ, Kim CK.

ORCID

Seung Chul Lee https://orcid.org/0000-0003-1221-958X
Soon Ho Yoon https://orcid.org/0000-0002-3700-0165
Jin Mo Goo https://orcid.org/0000-0003-1791-7942
Jae-Joon Yim https://orcid.org/0000-0002-9605-0074
Chang-Ki Kim https://orcid.org/0000-0003-4729-3114

REFERENCES

1. World Health Organization. Global tuberculosis report 2015 [Internet]. Available at http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf [accessed on 29 August 2017].
2. Kim HJ, Yoon HH, Eun BW, Ahn Y, Ryoo S, Kim HJ. The rate of drug-resistant tuberculosis in Korean children and adolescents since 2007. J Korean Med Sci 2017; 32: 954-60.
3. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, Jenkinson P, Bayona J, Dartois V. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1380-43.
4. Shah NS, Yuen CM, Heo M, Tolman AW, Becerra MC. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2014; 58: 381-91.
5. Becerra MC, Appleton SC, Franke MF, Chalco K, Arteaga F, Bayona J, Murray M, Atwood SS, Mitrick CD. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 2011; 377: 147-52.
6. van der Werf MJ, Langendam MW, Sandgren A, Maniessos D. Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews. Int J Tuberc Lung Dis 2012; 16: 288-96.
7. Langendam MW, Tiemersma EW, van der Werf MJ, Sandgren A. Adverse events in healthy individuals and MDR-TB contacts treated with anti-tuberculosis drugs potentially effective for preventing development of MDR-TB: a systematic review. PLoS One 2013; 8: e53599.
8. Falzon D, Jaramillo E, Schimmelman HJ, Arenz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley C, Duncombe C, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-28.
9. Barry CE 3rd, Boshoff H, Dartois V, Dick T, Ehr T, Flynn L, Schnappinger D, Wilkinson RJ, Young D. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009; 7: 845-55.
10. Lee SW, Jang YS, Park CM, Kang HJ, Koh WJ, Yim JJ, Jeon K. The role of chest CT scanning in TB outbreak investigation. Chest 2010; 137: 1057-64.
11. Petruccioli E, Scriba TJ, Petrone L, Hatherill M, Criollo DM, Joosten SA, Ottenhoff TH, Denkinger CM, Goletti D. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur Respir J 2016; 48: 1751-63.
12. Alshurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis 2016; 16: 1269-78.
13. Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med 2007; 357: 2277-84.
14. Deak PD, Smal Y, Kalender WA. Multisecton CT protocols: sex- and age-specific conversion factors used to determine effective dose from dose-length product. Radiology 2010; 257: 158-66.
15. Pearce MS, Salotti JA, Little MP, McHugh K, Schnappinger D, Wilkinson RJ, Young D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis 2016; 16: 1269-78.
16. Mettler FA Jr, Huda W, Yoshihumi TT, Mahesh M. Effective doses in radiology, diagnostic nuclear medicine: a catalog. Radiology 2008; 248: 254-63.
17. Lenaerts A, Barry CE 3rd, Dartois V. Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev 2015; 264: 288-307.
18. Im JG, Itoh H, Shim YS, Lee JH, Ahn J, Han MC, Noma S. Pulmonary tuberculosis drugs potentially effective for preventing development of MDR-TB contacts of multidrug-resistant tuberculosis patients: a TBNET study. PLoS One 2013; 8: e53599.
19. Yoon CG, Oh SY, Lee JB, Kim MH, Seo Y, Yang J, Bae KJ, Hong S, Yang ES, Kim HJ. Occupational risk of latent tuberculosis infection in health workers of 14 military hospitals. J Korean Med Sci 2017; 32: 1251-7.
20. de Visser V, Sotgiu G, Lange C, Aabye MG, Bakker M, Bartalesi F, Brat K, Chee CB, Dheda K, Dominguez J, et al. False-negative interferon-γ release assay results in active tuberculosis: a TBNET study. Eur Respir J 2015; 45: 279-83.
SUPPLEMENTARY MATERIAL

Supplementary 1. Full technical details of contact investigation, bacteriology and genotyping

Contact investigation
To exclude active tuberculosis (TB), contact investigation was done with the sputum test and chest radiograph. For contacts excluded from active TB, the latent TB infection (LTBI) test was first performed with a tuberculin skin test, followed by an interferon gamma release assay (IGRA) for contacts having a positive tuberculin skin test. This was the national guideline for diagnosis of LTBI, considering that Bacillus Calmette-Guérin vaccination is mandatory in Korea. A follow-up investigation was planned 3 months and 1 year after baseline examination. At the 3-month follow-up, a second tuberculin skin test and IGRA test were performed in those who were negative on initial LTBI tests.

Tuberculin skin tests were performed on the volar side of the forearm by administration of two units of tuberculin purified protein derivative-RT23, with any induration measured in millimeters between 48 and 72 hours, using the ballpoint method. A QuantiFERON-TB Gold In-Tube test (Qiagen, Hilden, Germany) was done per manufacturer instructions. Cutoffs for positivity on tuberculin skin test and IGRA (corrected for nil response) were 10 mm and 0.35 IU/mL, respectively.

Bacteriology and genotyping
Close contacts submitted sputum, and specimens were microscopically examined for acid-fast bacillus with auramine-rhodamine fluorescent staining and confirmed by Ziehl-Neelsen staining. The Xpert/RIF test (Cepheid, Sunnyvale, CA, USA) was performed according to manufacturer instructions within 24 hours of sputum submission. Sputum culture was done with the national reference standard quality with solid culture on 3% Ogawa media for 8 weeks and liquid culture in BACTEC™ MGIT™ (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) for 6 weeks. Confirmed diagnosis of TB was determined if Mycobacterium tuberculosis was isolated in at least one solid or liquid culture.

Drug susceptibility test and genotyping were performed at the supranational reference laboratory for TB, the Korean Institute of Tuberculosis. The resistance to each anti-TB drug was defined as greater than 1% bacterial growth in Lowenstein-Jensen medium (Thermo Scientific, Waltham, MA, USA) using the absolute concentration method with following critical concentrations: isoniazid 0.2 µg/mL; streptomycin 10.0 µg/mL; ethambutol 2.0 µg/mL; rifampicin 40.0 µg/mL; paraaminosalicylic acid 1.0 µg/mL; prothionamide 40.0 µg/mL; cycloserine 30.0 µg/mL; kanamycin 30.0 µg/mL; capreomycin 40.0 µg/mL; ofloxacin 4.0 µg/mL; levofloxacin 2.0 µg/mL; moxifloxacin 2.0 µg/mL; and rifabutin 20 µg/mL. Pyrazinamide susceptibility was assessed through a pyrazinamidase test. TB isolates were genotyped from index case and contacts with culture-positive TB, using spacer oligonucleotide typing (spoligotyping) and 24-loci mycobacterial interspersed repetitive unit-variable-number tandem repeat analysis.

REFERENCE
1. Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rüscher-Gerdes S, Willery E, Savine E, de Haas P, van Deutekom H, Roring S, et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44: 4498-510.